Indication

Invasive bladder cancer

Invasive bladder cancer is a malignant neoplasm of the urinary system originating in the urothelium that has penetrated past the basement membrane into deeper anatomical layers of the bladder wall. Read more about Invasive bladder cancer

51 drugs 33 manufacturers

Advertisement

Drugs that treat it

Common Invasive bladder cancer therapies.

Showing 37–45 of 51 drugs

DOXORUBICIN HCL

ANTHRACYCLINE ANTIBIOTICS·OSTEOSARCOMA OF BONE·+19
Laboratories Div

CISPLATIN

PLATINUM COMPOUNDS·OVARIAN GERM CELL TUMOR CARCINOMA·+5
SAGENT PHARMACE

CISPLATIN

PLATINUM COMPOUNDS·OVARIAN GERM CELL TUMOR CARCINOMA·+5
APOTEX CORP

CISPLATIN

PLATINUM COMPOUNDS·OVARIAN GERM CELL TUMOR CARCINOMA·+5
FOSUN PHARMA US

DOXORUBICIN HCL

ANTHRACYCLINE ANTIBIOTICS·OSTEOSARCOMA OF BONE·+19
Hikma Pharmaceuticals USA

DOXORUBICIN HCL

ANTHRACYCLINE ANTIBIOTICS·OSTEOSARCOMA OF BONE·+19
WEST-WARD/HI-NO
Filter & compare in the drug finder →Opens the drug finder with Invasive bladder cancer preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Invasive bladder cancer.

Invasive bladder cancer is a malignant neoplasm of the urinary system originating in the urothelium that has penetrated past the basement membrane into deeper anatomical layers of the bladder wall.

It most commonly affects older adults and is characterized pathophysiologically by tumor extension into the subepithelial connective tissue, the muscularis propria (detrusor muscle), or beyond into perivesical fat and adjacent pelvic organs.

Clinically presenting with gross or microscopic hematuria and lower urinary tract symptoms, this advanced stage carries a substantially higher risk of lymphatic dissemination and distant metastases compared to superficial urothelial lesions.

Personalize your experience

Follow Invasive bladder cancer and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it